Recruiting PHASE2 Obsessive-Compulsive Disorder

New treatment option for Obsessive-Compulsive Disorder

Official title MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)

ClinicalTrials.gov ID: NCT05783817

What this study is testing

What is 3,4-Methyl enedioxy methamphetamine?

3,4-Methyl enedioxy methamphetamine is an investigational medicine, being studied as a potential treatment for obsessive-compulsive disorder.

Also referred to as MDMA.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The study assesses the safety and preliminary effectiveness of MDMA-assisted cognitive behavioral therapy in participants diagnosed with obsessive-compulsive disorder (OCD).
  • Phase 2: a mid-size study of how well it works

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 and older

You may be able to join if

  • At least 18 years old
  • Fluent in speaking and reading the predominantly used or recognized language of the study site
  • Able to swallow pills
  • Meet the criteria for OCD diagnosis
  • YBOCS total score of at least 16

You likely can't join if

  • Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
  • Weigh less than 48 kilograms (kgs)
  • Any current problem which, in the opinion of the investigator or study physician, might interfere with participation
See the full eligibility criteria
Who can join
  • At least 18 years old
  • Fluent in speaking and reading the predominantly used or recognized language of the study site
  • Able to swallow pills
  • Meet the criteria for OCD diagnosis
  • YBOCS total score of at least 16
  • Not on psychotropic medications 1 month prior to study enrollment
  • Able to tolerate a treatment-free period
  • Able to tolerate study procedures
  • Failed at least 1 prior trial of standard first-line OCD treatment
  • Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to the Experimental Session, not enroll in any other treatment clinical trials during...
What rules you out
  • Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
  • Weigh less than 48 kilograms (kgs)
  • Any current problem which, in the opinion of the investigator or study physician, might interfere with participation

The study team makes the final eligibility decision.

Where it's taking place

  • Palo Alto, California, United States

Compensation & support

A stipend or compensation may be offered.

Compensation mentioned.

ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.

Questions & answers

Do participants get paid in this trial?

This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Palo Alto, California, United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.